http://purl.uniprot.org/citations/34775477 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
http://purl.uniprot.org/citations/34775477 | http://www.w3.org/2000/01/rdf-schema#comment | "No biomarkers are available to predict patients at risk of developing hypertension induced by VEGF-pathway inhibitors. This study aimed to identify predictive biomarkers of hypertension induced by these drugs using a discovery-replication approach. The discovery set included 140 sorafenib-treated patients (TARGET study) genotyped for 973 SNPs in 56 genes. The most statistically significant SNPs associated with grade ≥2 hypertension were tested for association with grade ≥2 hypertension in the replication set of a GWAS of 1039 bevacizumab-treated patients from four clinical trials (CALGB/Alliance). In the discovery set, rs444904 (G > A) in PIK3R5 was associated with an increased risk of sorafenib-induced hypertension (p = 0.006, OR = 3.88 95% CI 1.54-9.81). In the replication set, rs427554 (G > A) in PIK3R5 (in complete linkage disequilibrium with rs444904) was associated with an increased risk of bevacizumab-induced hypertension (p = 0.008, OR = 1.39, 95% CI 1.09-1.78). This study identified a predictive marker of drug-induced hypertension that should be evaluated for other VEGF-pathway inhibitors.ClinicalTrials.gov Identifier:NCT00073307 (TARGET)."xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.org/dc/terms/identifier | "doi:10.1038/s41397-021-00261-5"xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/author | "Lin D."xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/author | "Wang J."xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/author | "Pena C.E."xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/author | "Innocenti F."xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/author | "Skol A.D."xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/author | "Etheridge A.S."xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/author | "Racioppi A."xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/author | "Denning S."xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/author | "Crona D.J."xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/author | "Quintanilha J.C.F."xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/date | "2022"xsd:gYear |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/name | "Pharmacogenomics J"xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/pages | "82-88"xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/title | "PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors."xsd:string |
http://purl.uniprot.org/citations/34775477 | http://purl.uniprot.org/core/volume | "22"xsd:string |
http://purl.uniprot.org/citations/34775477 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/34775477 |
http://purl.uniprot.org/citations/34775477 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/34775477 |
http://purl.uniprot.org/uniprot/#_L7RT34-mappedCitation-34775477 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/34775477 |
http://purl.uniprot.org/uniprot/#_Q8WYR1-mappedCitation-34775477 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/34775477 |
http://purl.uniprot.org/uniprot/L7RT34 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/34775477 |
http://purl.uniprot.org/uniprot/Q8WYR1 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/34775477 |